The Science and Clinical Success Behind Eeva
The Eeva Test was developed based on landmark research conducted at Stanford University which discovered that early cell division events can predict embryo developmental outcome and reflect the underlying molecular health of the embryo.
The research measured the time it took each embryo to achieve specific cell development milestones during the first two days after fertilisation in vitro. This led to the discovery of precise cell-division timing parameters that could non-invasively predict on Day 3 which embryos were most likely to develop to blastocyst stage on Day 5.
The safety and efficacy of Eeva were validated in a prospective, multi-center, 54-patient clinical trial; results of which were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey. In the study, Eeva was able to predict blastocyst formation at the cleavage stage with 85 per cent specificity, reducing the false positive rate from 43 per cent to 15 per cent compared with traditional morphology selection. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists.
Auxogyn received CE mark approval to market Eeva in the EU in July 2012. Eeva is currently approved and available for use only in the EU. It is not yet cleared in the United States and is limited to investigational use only.